UK, US drugmakers scrap 'futile' Alzheimer's treatment trial

June 12, 2018

British and American pharmaceutical giants AstraZeneca and Eli Lilly on Tuesday said they were ending a large clinical trial of a treatment for Alzheimer's that they had been developing jointly.

The decision to scrap the phase III clinical trial comes as a major setback in the race to find a cure for the disease, which is the most common form of dementia and affects millions of people around the world.

With a clinical trial failure rate of over 99 percent, there is still no licenced drug that slows Alzheimer's progression or cures it.

"We are saddened by this outcome as our researchers are working tirelessly to find a solution for the many people who are impacted by this devastating disease," Menelas Pangalos, executive vice president of AstraZeneca said in a statement.

"We won't give up on finding a solution for Alzheimer's patients," Daniel Skovronsky, president of Lilly Research Labs added.

The two firms announced a partnership to develop a new drug aimed at combatting Alzheimer's in 2014.

They were working on two treatments—one for patients with early Alzheimer's disease, the other for those with mild Alzheimer's disease dementia.

Both treatments used a so-called "inhibitor" targeting an enzyme called BACE.

Multiple blows

According to the statement, an independent data monitoring committee ruled that both the treatments "were not likely to meet their primary end-points upon completion and therefore should be stopped for futility".

The statement also said the discontinuation of the trials was not expected to have any financial impact on the firms' outlook for 2018.

Health systems in Western countries are struggling to deal with Alzheimer's as it is costly to treat sufferers of the incurable disease which leaves them increasingly reliant on assistance.

US pharmaceutical behemoth Pfizer announced in January it was pulling out of neuroscience research entirely.

Swiss giants Roche and Axovant, as well US firm Merck have all tried unsuccessfully to come up with the solution to Alzheimer's.

According to the World Health Organization, some 50 million people around the world have dementia, with Alzheimer's accounting for 60-70 percent of the cases.

As the world's population ages, the number of patients is expected to double by 2030 and to triple by 2050 if no cure is found.

The global cost of caring for sufferers was set to reach $1 trillion (850 billion euros) this year.

According to the Alzforum website, which gathers data on candidate drugs, fewer than 300 have made it to Phase II trials so far.

Only five have ever been approved to treat symptoms such as memory loss associated with Alzheimer's, a disease first identified more than 100 years ago.

"Although dementia mainly affects older people, it is not a normal part of ageing," the WHO says on its website.

"Dementia has a physical, psychological, social, and economic impact, not only on people with dementia, but also on their carers, families and society at large," it adds.

Explore further: Study predicts most people with earliest Alzheimer's signs won't develop dementia associated with the disease

Related Stories

Study predicts most people with earliest Alzheimer's signs won't develop dementia associated with the disease

May 22, 2018
During the past decade, researchers have identified new ways to detect the earliest biological signs of Alzheimer's disease. These early signs, which are detected by biomarkers, may be present before a person starts to exhibit ...

Merck halts trial of once 'promising' Alzheimer's drug

February 15, 2017
US pharmaceutical giant Merck announced it is halting a clinical trial on a drug once touted as a promising treatment for Alzheimer's disease, saying studies show it does not work.

New forecast shows 6 million with Alzheimer's disease, cognitive impairment

December 8, 2017
Using new methodology, scientists calculate that approximately 6 million American adults have Alzheimer's disease or mild cognitive impairment, which can sometimes be a precursor to the disease. The estimate, funded by the ...

Arthritis drugs linked to lower Alzheimer's risk

February 13, 2018
Scientists from the University of Southampton have teamed up with researchers from the University of Oxford to look at whether existing drugs for arthritis have any effect on a person's risk of developing dementia. By looking ...

Rocky start for Alzheimer's drug research in 2018

January 19, 2018
The year 2018, barely underway, has already dealt a series of disheartening blows to the quest for an Alzheimer's cure.

Alzheimer's drug targeting soluble amyloid falls short in a large clinical trial

January 25, 2018
A paper published today in the New England Journal of Medicine reports that solanezumab, a monoclonal antibody-based treatment for Alzheimer's disease developed by Eli Lilly that targets amyloid plaques, did not significantly ...

Recommended for you

Hypothesis underpinning dementia research 'flawed'

October 16, 2018
A hypothesis which has been the standard way of explaining how the body develops Alzheimer's Disease for almost 30 years is flawed, according to a University of Manchester biologist.

Many cases of dementia may arise from non-inherited DNA 'spelling mistakes'

October 15, 2018
Only a small proportion of cases of dementia are thought to be inherited—the cause of the vast majority is unknown. Now, in a study published today in the journal Nature Communications, a team of scientists led by researchers ...

Scientists create new map of brain region linked to Alzheimer's disease

October 8, 2018
Curing some of the most vexing diseases first requires navigating the world's most complex structure—the human brain. So, USC scientists have created the most detailed atlas yet of the brain's memory bank.

Previously unknown genetic aberrations found to be associated with Alzheimer's progression

October 8, 2018
In a large-scale analysis of RNA from postmortem human brain tissue, researchers at the Icahn School of Medicine at Mount Sinai and Columbia University have identified specific RNA splicing events associated with Alzheimer's ...

Periodontal disease bacteria may kick-start Alzheimer's

October 4, 2018
Long-term exposure to periodontal disease bacteria causes inflammation and degeneration of brain neurons in mice that is similar to the effects of Alzheimer's disease in humans, according to a new study from researchers at ...

AI could predict cognitive decline leading to Alzheimer's disease in the next five years

October 4, 2018
A team of scientists has successfully trained a new artificial intelligence (AI) algorithm to make accurate predictions regarding cognitive decline leading to Alzheimer's disease.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.